A nucleotide polymorphism in ERCC1 in human ovarian cancer cell lines and tumor tissues

被引:96
作者
Yu, JJ [1 ]
Mu, CJ [1 ]
Lee, KB [1 ]
Okamoto, A [1 ]
Reed, EL [1 ]
Bostick-Bruton, F [1 ]
Mitchell, KC [1 ]
Reed, E [1 ]
机构
[1] NCI, Med Branch, Dev Therapeut Dept,Div Clin Sci, Med Ovarian Canc Sect, Bethesda, MD 20892 USA
来源
MUTATION RESEARCH-GENOMICS | 1997年 / 382卷 / 1-2期
关键词
nucleotide excision repair; codon usage; polymorphism; single strand conformation polymorphism; sequence; ovarian cancer;
D O I
10.1016/S1383-5726(97)00004-6
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
We studied the DNA sequence of the entire coding region of ERCC1 gene, in five cell lines established from human ovarian cancer (A2780, A2780/CP70, MCAS, OVCAR-3, SK-OV-3), 29 human ovarian cancer tumor tissue specimens, one human T-lymphocyte cell line (H9), and non-malignant human ovary tissue (NHO). Samples were assayed by PCR-SSCP and DNA sequence analyses. A silent mutation at codon 118 (site for restriction endonuclease MaeII) in exon 4 of the gene was detected in MCAS, OVCAR-3 and SK-OV-3 cells, and NHO. This mutation was a C --> T transition, that codes for the same amino acid: asparagine, This transition converts a common codon usage (AAC) to an infrequent codon usage (AAT), whereas frequency of use is reduced two-fold. This base change was associated with a detectable band shift on SSCP analysis. For the 29 ovarian cancer specimens, the same base change was observed in 15 tumor samples and was associated with the same band shift in exon 4. Cells and tumor tissue specimens that did not contain the C --> T transition, did not show the band shift in exon 4. Our data suggest that this alteration at codon lie within the ERCC1 gene, may exist in platinum-sensitive and platinum-resistant ovarian cancer tissues. (C) 1997 Elsevier Science B.V.
引用
收藏
页码:13 / 20
页数:8
相关论文
共 29 条
[2]   IT WAS A VERY GOOD YEAR FOR DNA-REPAIR [J].
CLEAVER, JE .
CELL, 1994, 76 (01) :1-4
[3]   EXPRESSION OF EXCISION REPAIR GENES IN NONMALIGNANT BONE-MARROW FROM CANCER-PATIENTS [J].
DABHOLKAR, M ;
BOSTICKBRUTON, F ;
WEBER, C ;
EGWUAGU, C ;
BOHR, VA ;
REED, E .
MUTATION RESEARCH, 1993, 293 (02) :151-160
[4]  
DABHOLKAR M, 1995, ONCOL REP, V2, P209
[5]   MESSENGER-RNA LEVELS OF XPAC AND ERCC1 IN OVARIAN-CANCER TISSUE CORRELATE WITH RESPONSE TO PLATINUM-BASED CHEMOTHERAPY [J].
DABHOLKAR, M ;
VIONNET, J ;
BOSTICKBRUTON, F ;
YU, JJ ;
REED, E .
JOURNAL OF CLINICAL INVESTIGATION, 1994, 94 (02) :703-708
[6]   WHERE TRANSCRIPTION MEETS REPAIR [J].
DRAPKIN, R ;
SANCAR, A ;
REINBERG, D .
CELL, 1994, 77 (01) :9-12
[7]  
HOEIJMAKERS JHJ, 1987, J CELL SCI, P111
[8]   FREQUENT MUTATION OF THE P53 GENE IN HUMAN ESOPHAGEAL CANCER [J].
HOLLSTEIN, MC ;
METCALF, RA ;
WELSH, JA ;
MONTESANO, R ;
HARRIS, CC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (24) :9958-9961
[9]  
JONES JC, 1991, J BIOL CHEM, V266, P7101